Diminished genotoxicity of mitomycin C and farmorubicin included in polybutylcyanoacrylate nanoparticles

Mutat Res. 1992 Jul;268(1):77-82. doi: 10.1016/0027-5107(92)90085-g.

Abstract

The genotoxic effects of mitomycin C (MMC) and farmorubicin (FR) in a free form and included in polybutylcyanoacrylate nanoparticles (PBCN) were studied employing the Salmonella/microsome mutagenicity assay and the micronucleus test in mouse bone marrow as well as in mouse fetal liver. The data obtained clearly indicated that MMC (0.25-2.00 micrograms/plate) was a strong mutagen in S. typhimurium TA102, while the same concentrations of this compound in PBCN were ineffective in inducing his+ revertant mutations in bacterial cells. A similar total suppression of mutagenic activity of FR (1.0-20.0 micrograms/plate) was registered in S. typhimurium TA98 when the drug was included in PBCN. Furthermore, the incorporation of MMC (2.0 or 4.0 mg/kg, i.p.) into PBCN strongly diminished or even abolished its clastogenic activity in the bone marrow of virgin and pregnant mice as well as in mouse fetal liver, respectively. In addition, a lack of genotoxic effect of PBCN only was also established. The toxic activity of MMC in mouse bone marrow was significantly reduced or completely abolished after its inclusion in PBCN. A conclusion might be drawn that the genotoxic activity of some antitumor drugs might be markedly diminished or even abolished after their incorporation in PBCN.

Publication types

  • Comparative Study

MeSH terms

  • Animals
  • Bone Marrow / drug effects
  • Drug Carriers
  • Enbucrilate*
  • Epirubicin / toxicity*
  • Female
  • Liver / drug effects
  • Liver / embryology
  • Maternal-Fetal Exchange
  • Mice
  • Micronuclei, Chromosome-Defective / drug effects
  • Micronucleus Tests
  • Mitomycin / toxicity*
  • Mutagenicity Tests
  • Mutagens / toxicity*
  • Pregnancy
  • Salmonella typhimurium / drug effects

Substances

  • Drug Carriers
  • Mutagens
  • Epirubicin
  • Mitomycin
  • Enbucrilate